Global Portfolio of Antimalarial Medicines, 2QResearch Development Translational Preclinical Preclinical Lead optimisation Phase I Human volunteers Phase IIa Patient exploratory Access Phase IIb/III Registration Patient confirmatory Under review * Oxaboroles 1 Project P218 MMV048 OZ439/PQP Tafenoquine Rectal Artesunate Anacor Novartis BIOTEC UCT/TIA Sanofi GSK CIPLA/Strides/TDR DHODH 3 Projects SJ733 ACT840 OZ439/FQ UTSW/UW/Monash GSK St Jude/Eisai Actelion Sanofi Open Source Drug Discovery Sydney Orthologue Leads Sanofi DDD498 Merck Serono (Dundee) Amino-alcohols Tetraoxanes PA92 Merck Serono LSTM/Liverpool (Drexel/UW/GNF) Imidazolidinediones WRAIR dUTPase inhibitors Medivir Pf.
Download ReportTranscript Global Portfolio of Antimalarial Medicines, 2QResearch Development Translational Preclinical Preclinical Lead optimisation Phase I Human volunteers Phase IIa Patient exploratory Access Phase IIb/III Registration Patient confirmatory Under review * Oxaboroles 1 Project P218 MMV048 OZ439/PQP Tafenoquine Rectal Artesunate Anacor Novartis BIOTEC UCT/TIA Sanofi GSK CIPLA/Strides/TDR DHODH 3 Projects SJ733 ACT840 OZ439/FQ UTSW/UW/Monash GSK St Jude/Eisai Actelion Sanofi Open Source Drug Discovery Sydney Orthologue Leads Sanofi DDD498 Merck Serono (Dundee) Amino-alcohols Tetraoxanes PA92 Merck Serono LSTM/Liverpool (Drexel/UW/GNF) Imidazolidinediones WRAIR dUTPase inhibitors Medivir Pf.
Global Portfolio of Antimalarial Medicines, 2Q 2015 Research Development Translational Preclinical Preclinical Lead optimisation Phase I Human volunteers Phase IIa Patient exploratory Access Phase IIb/III Registration Patient confirmatory Under review * Oxaboroles 1 Project P218 MMV048 OZ439/PQP Tafenoquine Rectal Artesunate Anacor Novartis BIOTEC UCT/TIA Sanofi GSK CIPLA/Strides/TDR DHODH 3 Projects SJ733 ACT840 OZ439/FQ UTSW/UW/Monash GSK St Jude/Eisai Actelion Sanofi Open Source Drug Discovery Sydney Orthologue Leads Sanofi DDD498 Merck Serono (Dundee) Amino-alcohols Tetraoxanes PA92 Merck Serono LSTM/Liverpool (Drexel/UW/GNF) Imidazolidinediones WRAIR dUTPase inhibitors Medivir Pf NMT Imperial College London Pf NDH2 LSTM/Liverpool Ipca N tert butyl isoquine LSTM/Liverpool/ GSK KAE609 Novartis KAF156 Novartis MMV253 DSM265 (AstraZeneca) Takeda Sigma-Tau GSK030 GSK (UTSW/UW/ Monash) Broad Institute NPC1161B Mississippi 4 Arterolane/PQP Ranbaxy** PyronaridineArtesunate Paediatric Co-trimoxazole Bactrim Inst. of Trop. Med. Shin Poong KPC 7 5 Heidelberg SAR97276 Sanofi LSTM/Liverpool JPC3210 Jacobus MK4815 Merck Artemisone UHKST AQ13 Immtech DF02 Dilafor 2 Novartis Artesunate for injection 3 Guilin 8 Sigma-Tau 4 PyronaridineArtesunate Artemether sublingual spray 9 5 Shin Poong Artesunate Amodiaquine 6 Sanofi/DNDi Included in MMV portfolio post approval Non MMV * First review or approval by WHO Prequalification, or by regulatory bodies who are ICH members or observers ** Approved in several countries not approved by SRA nor WHO prequal ArtesunateMefloquine CIPLA/DNDi SulfadoxinePyrimethamine+ Amodiaquine Guilin RKA182 1 ArtemetherLumefantrine Dispersible DHA-Piperaquine Fosmidomycin Piperaquine Jomaa Pharma GmbH Methylene Blue/AQ ArtemetherLumefantrine Novartis Artemisinin Naphthoquine** ProtoPharma Ltd DSM421 Diversity Oriented Synthesis CDRI 9778 DHA-Piperaquine Pediatric Phase Post IV approval 10 1 Brand name: Coartem®, generics by Ajanta, Cipla, Ipca, Strides, Macleods Pharma Ltd, Mylan Laboratories 2 Brand name: Coartem® Dispersible, generics by Ajanta 3 Brand name: Artesun® 4 Brand name: Eurartesim® 5 Brand name: Pyramax® 6 Brand names: CoarsucamTM, ASAQ/Winthrop®, generics by Ajanta, Ipca, Guilin, Cipla, Strides (co-blistered) 7 Brand name: SynriamTM 8 Brand name: ARCO® 9 Brand name: ArTiMistTM